logo

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 12076345 B1

PDFFull Text
Date of Patent:
Sep. 03, 2024

Filed:

May. 27, 2022

Method for treating multiple sclerosis with peptide-loaded dendritic cells

Applicant:

Avotres, Inc., Cedar Knolls, NJ (US);

Inventor:

Hong Jiang, Fort Lee, NJ (US);

Assignee:

Avotres, Inc., Cedar Knolls, NJ (US);

Attorney:

Buchanan Ingersoll & Rooney PC

Primary Examiner:

Laura Schuberg

Int. Cl.
CPC ...
A61K 35/15 (2015.01); A61K 31/10 (2006.01); A61K 35/17 (2015.01); A61K 38/17 (2006.01); A61K 38/38 (2006.01); A61K 47/20 (2006.01); A61K 47/42 (2017.01); A61P 17/06 (2006.01); A61P 19/02 (2006.01); A61P 25/28 (2006.01); A61P 37/02 (2006.01); A61P 37/04 (2006.01); A61P 37/06 (2006.01); C07K 14/74 (2006.01); C12N 5/0783 (2010.01); C12N 5/0784 (2010.01); G01N 33/50 (2006.01);
U.S. Cl.
CPC ...
A61K 35/17 (2013.01); A61K 31/10 (2013.01); A61K 35/15 (2013.01); A61K 38/1709 (2013.01); A61K 38/38 (2013.01); A61K 47/20 (2013.01); A61K 47/42 (2013.01); A61P 17/06 (2018.01); A61P 19/02 (2018.01); A61P 25/28 (2018.01); A61P 37/02 (2018.01); A61P 37/04 (2018.01); A61P 37/06 (2018.01); C07K 14/70539 (2013.01); C12N 5/0637 (2013.01); C12N 5/0639 (2013.01); G01N 33/505 (2013.01); C12N 2501/22 (2013.01); C12N 2501/2304 (2013.01);
Abstract

The present invention provides a composition comprising dendritic cells loaded with hHsp60sp, which dendritic cells are from a subject and have been fixed with paraformaldehyde (PFA). The subject may suffer from an autoimmune disease. Also provided are a method for preparing the composition; recombinant human cells comprising a heterologous gene encoding a fusion protein of HLA-E and hHsp60sp or B7sp, and expressing the fusion protein on the surface of the cells; a method for determining a percentage of maximum inhibition of testing the function of the HLA-E restricted CD8+ Treg cells from a subject, determining whether HLA-E restricted CD8+ Treg cells freshly isolated from a subject are defective, or determining whether defective HLA-E restricted CD8+ Treg cells from a subject are correctable; and a method for correcting defective HLA-E restricted CD8+ Treg cells, treating type 1 diabetes (T1D), or treating multiple sclerosis (MS).

Find Patent Forward Citations

Loading…